Background: The repetitive ischemia and reperfusion may induce cell and tissue protection against the reperfusion-related injuries. This process, known as the post-ischaemic preconditioning (IPC), can be observed in different tissues and organs, including heart, muscles or skin. During ischemia leading to cellular hypoxia/anoxia, the amount of NADH gradually increases. During the reperfusion and restoration of oxygen, the amount of NADH drops down as it turns to NADþ in the process of passing both hydrogen and electrons to oxygen within mitochondria. NADH can emit fluorescence light at the length of 460 nm, thus by measuring such fluorescence, it is possible to quantify the amount of NADH. This study aimed to assess non-invasively the presence of IPC in the human skin by quantifying the flow-mediated skin fluorescence at the length of 460 nm (FMSF) at rest, during repeated ischemia and reperfusion episodes. Methods: We studied 99 healthy people (23.6þ/-7.8 years old; 55 women) who underwent a non-invasive and in vivo measurement of the FMSF at rest, and then three times during 100-second brachial artery occlusions (blood pressure cuff inflated to the pressure 60 mmHg above each subject's systolic blood pressure) producing forearm ischemia (Isch), and the subsequent 10-minute reperfusion (Rep). To study IPC effects on the NADH, we compared the reperfusion related changes in FMSF after the first and third episode of ischemia by measuring: (1) the reperfusion magnitude (RepM), (2) the contribution of the reperfusion to the total change in FMSF during ischemia and reperfusion (RepCont), and (3) the half-time of the recovery of FMSF to the baseline during the reperfusion (tRep). Results were compared by the paired nonparametric Wilcoxon test and presented as median and the 25th-75th percentile (IQR). 
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Evaluation of anti-arrhythmic efficacy of the IK1 inhibitor PA-6 in domestic dogs with chronic atrial fibrillation The inward rectifier inhibitor pentamidine analogue 6 (PA-6) is effective in cardioversion of anaesthetised goats with persistent rapid pacing induced atrial fibrillation (AF) and is not pro-arrhythmic in anaesthetised experimental dogs with chronic third-degree AV block. However, efficacy and safety in the clinical setting is unknown. Purpose: To test efficacy and safety of PA-6 in converting AF to sinus rhythm (SR) in awake dogs with naturally occurring AF. Methods: Ten giant and large breed dogs (8 males; 57.7616.6 kg; 7.462.6 year) with persistent or permanent AF (mean duration of AF 5.866.5 month (range 1-19 months)) were included. PA-6 was applied i.v. as a bolus of 2.5 mg.kg-1.10min-1 followed by a maintenance infusion of 0.04 mg.kg-1.min-1 for a maximum of 50 minutes under awake conditions. Standard three lead ECG (I, II and III) was recorded during the entire procedure. Visible and audible signs of adverse effects were scored during the entire procedure. Results: PA-6 did not change QRS duration of QTc interval. RR interval was lengthened at the end of the bolus (363685 vs. 441696 ms). No cardioversion to SR was observed. Three dogs did not display any adverse effects. Five dogs showed premature ventricular contractions during PA-6 infusion. Respiratory distress and laryngeal stridor, muscle twitch and weakness were the main non-cardiac adverse effects observed in five dogs. Adverse effects resolved spontaneously and follow up was unremarkable. Conclusions: Chronic naturally occurring AF in large and giant breed dogs could not be cardioverted to SR by PA-6. Further clinical testing must first focus on paroxysmal AF under conditions of anesthesia and artificial ventilation. 3 Imperial College London, National Heart and Lung Institute, London, United Kingdom Funding Acknowledgements: Tekes, Academy of Finland, Sigrid Juselius Foundation, Finnish Foundation for Cardiovascular Research Introduction: Cardiac transcription factors, such as GATA4, NKX2-5, and TBX5, are key regulators of cardiac development. They also play an important role in the development of pathological conditions such as cardiomyopathy and left ventricular hypertrophy and are therefore considered attractive drug targets. We have recently described a new family of GATA4-targeted compounds that have shown potential against myocardial remodeling. To reduce the risk of toxicity-dependent failure at later stages of drug development, effective toxicity screening using precise cell models can be useful. Purpose: The purpose of this study was to investigate the in vitro toxicity and structure-toxicity relationships of the novel GATA4-targeted compounds, and to compare different cardiac and stem cell models in toxicity testing. Methods: Cell viability was studied in eight cell types: the H9c2 myoblast cell line, primary neonatal rat ventricular cardiomyocytes and fibroblasts, mouse embryonic stem cells (mESCs), mouse embryonic fibroblasts, mESC-derivatives from day 5 embryoid bodies, human induced pluripotent stem cells (hiPSCs) and hiPSC-derived cardiomyocytes (hiPSC-CMs). The cells were exposed to test compounds for 24 hours and the lactate dehydrogenase (LDH) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays were carried out to investigate necrosis and mitochondrial redox metabolism, respectively. Based on these results two compounds were chosen for high-content analysis of cell viability and proliferation using hiPSCs and hiPSC-CMs. For this, cell viability was assessed with staining for mitochondrial membrane potential, whereas proliferation was investigated with bromodeoxyuridine and Ki67 stainings. Results: None of the compounds induced necrotic cell death even at the highest concentration studied (30 mM). The MTT assay however revealed significant structure-dependent and cell typespecific toxicity profiles for the structurally related compounds. None of the compounds were toxic to H9c2 cells, cardiomyocytes or fibroblasts, while compounds possessing a 6-member ring in the southern part of the molecule were concentration-dependently toxic to stem and progenitor cells. As an example, the lead compound 3i-0666 induced a significant reduction in cell viability in hiPSCs (93-94% at 3 mM, P<0.001) but had no effect on cell viability in hiPSC-CMs (Fig. 1) . It also induced a 2.7-fold (P¼0.100) increase in cells positive for a fluorescent caspase reporter, indicating that stem cell death caused by some of the GATA4-targeted compounds is at least partially caspase-dependent. Conclusions: The cell types used for toxicity screening have a major impact on the results and should thus be chosen carefully. Stem cells provide the most sensitive model for toxicity screening. Identification of structural features responsible for stem cell toxicity in GATA4-targeted compounds allows further drug development towards non-toxic derivatives. Abstract P293 Figure Hypertension (HT) and rheumatoid arthritis (RA) are regarded as a conditions associated with higher risk for cardiovascular disease. L-arginine improves endothelial function and thereby is expected to be used in the prevention of cardiovascular disease. In addition, data exists that L-arginine aspartate can reduce insulin resistance and affects on the exchange of adipose tissue. We aimed to evaluate the effects of oral L-arginine supplementation on endothelial function, insulin resistance, adiponectin level in HT females comorbid with RA. 112 females with mean age -53,8 [49,6; 57,5] years were enrolled. Pts were randomized to study subgroup (n¼58) received L-Arginine aspartate 30 ml/day during 4 weeks in addition to standard treatment. Control subgroup pts (n¼54) received only the standard treatment. The levels of adiponectin, insulin were measured using ELISA kit test, insulin resistance was estimated using HOMA2 index. Endothelial-dependent flow mediated vasodilatation (EDVD) by D. Celermajer method was performed. All measuring were done at baseline and after 4 weeks. Statistical analysis included non-parametric methods with p value < 0.05. EDVD improved by 59,9% (p¼0.001) in L-arginine treatment group, in compare in control group -by 21,7% (p>0,05). Endothelial function had been normalized in 70,7% (p¼0.03) and 18,5% (p¼0.04) pts study and control group respectively. After 4 week L-Arginine supplementation the level of insulin resistance was significantly decreased by 10.4% (p¼0.01) in the treatment group. In pts with EDVD achieving 10% HOMA2 index decreased by 29.6% (p¼0.02). The adiponectin level was significantly increased by 12,3% (p¼0.001) in L-arginine treatment group. 
